Previous close | 5.15 |
Open | 5.20 |
Bid | 5.05 x 400 |
Ask | 5.09 x 2900 |
Day's range | 5.06 - 5.34 |
52-week range | 4.82 - 9.07 |
Volume | |
Avg. volume | 3,320,221 |
Market cap | 1.064B |
Beta (5Y monthly) | 1.92 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.16 |
Earnings date | 01 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 13.82 |
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m. ET. Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media s
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees stock options to purchase an aggregate of 16,050 shares, and restricted stock units (RSUs) covering an aggregate of 11,300 shares, of BioCryst common stock. The options and RSUs were granted as of February 29, 2024, as inducements material to each employee entering into e